Unmet needs in severe chronic upper airway disease (SCUAD)

Jean Bousquet, Claus Bachert, Giorgio W Canonica, Thomas B Casale, Alvaro A Cruz, Richard J Lockey, Torsten Zuberbier, David Price (Collaborator), Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Although the majority of patients with chronic upper airway diseases have controlled symptoms during treatment, many patients have severe chronic upper airway diseases (SCUADs). SCUAD defines those patients whose symptoms are inadequately controlled despite adequate (ie, effective, safe, and acceptable) pharmacologic treatment based on guidelines. These patients have impaired quality of life, social functioning, sleep, and school/work performance. Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs. Pediatric SCUADs are still unclear. In developing countries SCUADs exist, but risk factors can differ from those seen in developed countries. Comorbidities are common in patients with SCUADs and might increase their severity. The present document is the position of a group of experts considering that SCUADs should be considered differently from mild chronic upper airway diseases. It reviews the state of the art, highlighting gaps in our knowledge, and proposes several areas for a better understanding, prevention, and management of SCUADs. This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases.
Original languageEnglish
Pages (from-to)428-433
Number of pages6
JournalJournal of Allergy and Clinical Immunology
Volume124
Issue number3
Early online date5 Aug 2009
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Pharmaceutical Economics
Occupational Diseases
Rhinitis
Developed Countries
Developing Countries
Aspirin
Comorbidity
Sleep
Quality of Life
Guidelines
Pediatrics
Therapeutics
Work Performance
Allergic Rhinitis

Keywords

  • allergens
  • aspirin
  • child
  • chronic disease
  • drug hypersensitivity
  • humans
  • nasal polyps
  • prevalence
  • quality of life
  • rhinitis, allergic, perennial
  • severity of illness index
  • sinusitis

Cite this

Bousquet, J., Bachert, C., Canonica, G. W., Casale, T. B., Cruz, A. A., Lockey, R. J., ... Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group (2009). Unmet needs in severe chronic upper airway disease (SCUAD). Journal of Allergy and Clinical Immunology, 124(3), 428-433. https://doi.org/10.1016/j.jaci.2009.06.027

Unmet needs in severe chronic upper airway disease (SCUAD). / Bousquet, Jean; Bachert, Claus; Canonica, Giorgio W; Casale, Thomas B; Cruz, Alvaro A; Lockey, Richard J; Zuberbier, Torsten; Price, David (Collaborator); Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group.

In: Journal of Allergy and Clinical Immunology, Vol. 124, No. 3, 09.2009, p. 428-433.

Research output: Contribution to journalArticle

Bousquet, J, Bachert, C, Canonica, GW, Casale, TB, Cruz, AA, Lockey, RJ, Zuberbier, T, Price, D & Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group 2009, 'Unmet needs in severe chronic upper airway disease (SCUAD)', Journal of Allergy and Clinical Immunology, vol. 124, no. 3, pp. 428-433. https://doi.org/10.1016/j.jaci.2009.06.027
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ et al. Unmet needs in severe chronic upper airway disease (SCUAD). Journal of Allergy and Clinical Immunology. 2009 Sep;124(3):428-433. https://doi.org/10.1016/j.jaci.2009.06.027
Bousquet, Jean ; Bachert, Claus ; Canonica, Giorgio W ; Casale, Thomas B ; Cruz, Alvaro A ; Lockey, Richard J ; Zuberbier, Torsten ; Price, David ; Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. / Unmet needs in severe chronic upper airway disease (SCUAD). In: Journal of Allergy and Clinical Immunology. 2009 ; Vol. 124, No. 3. pp. 428-433.
@article{e39d016c01464f9ba2d54e7a5b7437e6,
title = "Unmet needs in severe chronic upper airway disease (SCUAD)",
abstract = "Although the majority of patients with chronic upper airway diseases have controlled symptoms during treatment, many patients have severe chronic upper airway diseases (SCUADs). SCUAD defines those patients whose symptoms are inadequately controlled despite adequate (ie, effective, safe, and acceptable) pharmacologic treatment based on guidelines. These patients have impaired quality of life, social functioning, sleep, and school/work performance. Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs. Pediatric SCUADs are still unclear. In developing countries SCUADs exist, but risk factors can differ from those seen in developed countries. Comorbidities are common in patients with SCUADs and might increase their severity. The present document is the position of a group of experts considering that SCUADs should be considered differently from mild chronic upper airway diseases. It reviews the state of the art, highlighting gaps in our knowledge, and proposes several areas for a better understanding, prevention, and management of SCUADs. This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases.",
keywords = "allergens, aspirin, child, chronic disease, drug hypersensitivity, humans, nasal polyps, prevalence, quality of life, rhinitis, allergic, perennial, severity of illness index, sinusitis",
author = "Jean Bousquet and Claus Bachert and Canonica, {Giorgio W} and Casale, {Thomas B} and Cruz, {Alvaro A} and Lockey, {Richard J} and Torsten Zuberbier and David Price and {Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group}",
year = "2009",
month = "9",
doi = "10.1016/j.jaci.2009.06.027",
language = "English",
volume = "124",
pages = "428--433",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby/Elsevier,",
number = "3",

}

TY - JOUR

T1 - Unmet needs in severe chronic upper airway disease (SCUAD)

AU - Bousquet, Jean

AU - Bachert, Claus

AU - Canonica, Giorgio W

AU - Casale, Thomas B

AU - Cruz, Alvaro A

AU - Lockey, Richard J

AU - Zuberbier, Torsten

AU - Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group

A2 - Price, David

PY - 2009/9

Y1 - 2009/9

N2 - Although the majority of patients with chronic upper airway diseases have controlled symptoms during treatment, many patients have severe chronic upper airway diseases (SCUADs). SCUAD defines those patients whose symptoms are inadequately controlled despite adequate (ie, effective, safe, and acceptable) pharmacologic treatment based on guidelines. These patients have impaired quality of life, social functioning, sleep, and school/work performance. Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs. Pediatric SCUADs are still unclear. In developing countries SCUADs exist, but risk factors can differ from those seen in developed countries. Comorbidities are common in patients with SCUADs and might increase their severity. The present document is the position of a group of experts considering that SCUADs should be considered differently from mild chronic upper airway diseases. It reviews the state of the art, highlighting gaps in our knowledge, and proposes several areas for a better understanding, prevention, and management of SCUADs. This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases.

AB - Although the majority of patients with chronic upper airway diseases have controlled symptoms during treatment, many patients have severe chronic upper airway diseases (SCUADs). SCUAD defines those patients whose symptoms are inadequately controlled despite adequate (ie, effective, safe, and acceptable) pharmacologic treatment based on guidelines. These patients have impaired quality of life, social functioning, sleep, and school/work performance. Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs. Pediatric SCUADs are still unclear. In developing countries SCUADs exist, but risk factors can differ from those seen in developed countries. Comorbidities are common in patients with SCUADs and might increase their severity. The present document is the position of a group of experts considering that SCUADs should be considered differently from mild chronic upper airway diseases. It reviews the state of the art, highlighting gaps in our knowledge, and proposes several areas for a better understanding, prevention, and management of SCUADs. This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases.

KW - allergens

KW - aspirin

KW - child

KW - chronic disease

KW - drug hypersensitivity

KW - humans

KW - nasal polyps

KW - prevalence

KW - quality of life

KW - rhinitis, allergic, perennial

KW - severity of illness index

KW - sinusitis

U2 - 10.1016/j.jaci.2009.06.027

DO - 10.1016/j.jaci.2009.06.027

M3 - Article

VL - 124

SP - 428

EP - 433

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -